Moderate

Multiple myeloma - management

myeloma mgmt · Haematology / Oncology
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

A clonal plasma cell malignancy causing the CRAB features (hypercalcaemia, renal impairment, anaemia, bone lesions). Modern therapy combines proteasome inhibitors, immunomodulatory drugs and anti-CD38 antibodies, with transplant in fit patients, achieving deep durable responses.

Figures & algorithms

Rouleaux
Rouleaux

Red flags

  • Spinal cord compression
  • Severe hypercalcaemia
  • Acute kidney injury / cast nephropathy
  • Hyperviscosity (visual, neurological change)
  • Febrile neutropenia

Assessment

Differential diagnosis

  • MGUS / smouldering myeloma
  • Waldenstrom macroglobulinaemia
  • AL amyloidosis
  • Metastatic bone disease
  • Other causes of renal failure/hypercalcaemia
  • Plasmacytoma

Investigations

  • Serum/urine protein electrophoresis and immunofixation, serum free light chains
  • FBC, calcium, renal function, albumin, beta-2 microglobulin, LDH
  • Bone marrow aspirate/trephine with plasma cell percentage, FISH cytogenetics
  • Whole-body MRI or low-dose CT/PET for lytic lesions
  • Serum viscosity if symptoms
  • Assessment for amyloid if suspected

Management

  • Confirm diagnosis using clonal plasma cells plus myeloma-defining events (CRAB or biomarkers)
  • Risk-stratify with ISS/R-ISS and cytogenetics
  • Treat emergencies first: hypercalcaemia, renal failure, cord compression, hyperviscosity
  • Assess transplant eligibility by age, fitness and comorbidity
  • Give induction with a triplet/quadruplet (e.g. daratumumab-bortezomib-lenalidomide-dexamethasone)
  • Proceed to autologous stem cell transplant in eligible patients, then lenalidomide maintenance
  • For transplant-ineligible patients give continuous novel-agent combinations
  • Provide bone protection with a bisphosphonate and treat/ prevent skeletal events
  • Give thromboprophylaxis with immunomodulatory drugs and antiviral prophylaxis with proteasome inhibitors/daratumumab
  • Manage relapse with alternative-class combinations, and consider CAR-T or bispecific antibodies in later lines

Drugs & doses

Bortezomib 1.3 mg/m2 SC weekly + lenalidomide 25 mg PO days 1-21 + dexamethasone 40 mg weekly (VRd backbone)
Daratumumab 1800 mg SC per schedule (added as quadruplet)
Lenalidomide 10-15 mg PO daily maintenance post-transplant
Zoledronic acid 4 mg IV every 3-4 weeks (bone protection; adjust for renal function)

Disposition

Haematology-led management; emergency admission for CRAB emergencies; ongoing outpatient therapy and transplant referral.

Complications & pitfalls

  • Renal failure (cast nephropathy)
  • Skeletal events and fractures
  • Infection/immunoparesis
  • Peripheral neuropathy (bortezomib)
  • Venous thrombosis (immunomodulatory drugs)
  • Secondary malignancy

Exam pearls

  • Daratumumab-based quadruplets are now standard first-line induction in many settings
  • Protect bones with bisphosphonates in all patients needing therapy
  • Immunomodulatory drugs mandate thromboprophylaxis
  • Autologous transplant deepens response in fit patients
  • Rising free light chains often herald relapse before organ damage

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.